Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations
Fabienne Lucas, Karilyn Larkin, Charles T. Gregory, Shelley Orwick, Tzyy-Jye Doong, Arletta Lozanski, Gerard Lozanski, Shrilekha Misra, Apollinaire Ngankeu, Hatice Gülçin Özer, Deepa Sampath, Shanmugapriya Thangavadivel, Selen Yilmaz, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach, James S. Blachly
Abstract
Lucas et al explored the clonal dynamics of chronic lymphocytic leukemia (CLL) patients following treatment and subsequent acquired resistance to ibrutinib and then venetoclax. They report different patterns of resistance mutations from previously reported changes following venetoclax treatment in the absence of prior BTK inhibitor therapy.
Topics & Concepts
VenetoclaxIbrutinibChronic lymphocytic leukemiaBruton's tyrosine kinaseCancer researchMedicineMutationSomatic evolution in cancerLeukemiaImmunologyBiologyGeneticsInternal medicineCancerTyrosine kinaseGeneReceptorChronic Lymphocytic Leukemia ResearchAdvanced Breast Cancer Therapies